Roche wins CE Mark for cobas smart e compact immunoanalyser
Roche has received the CE Mark for its cobas smart e immunoanalyser, a compact benchtop instrument designed to deliver the same immunoassay performance as the company's high-throughput central laboratory platforms in a footprint of under one square metre. The approval, announced on 27 October 2026, completes the Swiss diagnostics giant's cobas immunoassay portfolio and targets a growing market of decentralised and under-resourced healthcare settings.
The cobas smart e runs at up to 60 tests per hour and is designed to sit alongside the existing cobas e 402 (120 tests per hour) and cobas e 801 (300 tests per hour) analytical units. All three instruments share the same universal reagent carriers and Roche's proprietary Elecsys electrochemiluminescence technology, which the company says ensures comparable results across hub-and-spoke laboratory networks. A planned menu of more than 100 assays spanning cardiometabolic, oncology and infectious disease applications is to be rolled out in sequential launches.
"For smaller hospitals and laboratories, maintaining central-lab quality has traditionally meant outsourcing tests," said Matt Sause, chief executive of Roche Diagnostics. "The cobas smart e immunoanalyser fits on a benchtop, bringing Roche's immunoassay standards directly into these care settings."
Workflow and infrastructure design
Beyond throughput figures, Roche has engineered the platform explicitly for settings where skilled labour and reliable utilities are scarce. The system requires only one minute of daily operator intervention and reduces hands-on maintenance time by up to two-thirds compared to previous-generation instruments, according to the company. An automated walk-away cycle of up to two hours on a 36-sample load is also cited. Structurally, the unit incorporates an integrated water tank, dust-protection engineering, and standard power compatibility, removing dependencies on centralised laboratory infrastructure that frequently constrain testing in rural or low-resource clinics.
The workforce rationale is grounded in a commonly cited World Health Organization projection of an 11 million global health worker shortfall by 2030. Roche positions the reduced operator burden as a direct response to that pressure, though how much real-world productivity uplift the cobas smart e delivers in variable staffing environments will require post-market evidence.
Market context
The decentralised diagnostics segment has attracted sustained investment since the COVID-19 pandemic accelerated demand for near-patient testing, and Roche faces competition from a range of established and emerging players. Siemens Healthineers, Abbott and Beckman Coulter each offer mid-volume immunoanalysers targeting the same hospital outreach and community laboratory tier, while a number of smaller instrument manufacturers have advanced benchtop electrochemiluminescence platforms in recent years. Roche's competitive argument rests primarily on reagent commonality across its portfolio: a laboratory that already uses cobas e 801 or e 402 instruments at a central site can, in principle, extend to the cobas smart e at satellite locations without introducing a second reagent supply chain or recalibrating result interpretation.
CE Mark approval covers the European Economic Area and a number of associated markets, and Roche exhibited the platform at the International Federation of Clinical Chemistry and Laboratory Medicine conference in New Delhi in late October 2026. The company has not stated a timeline for submissions in the United States or other major regulatory jurisdictions, and the full 100-plus assay menu will not be available at launch, with Roche noting a phased rollout. Analysts and procurement leads will be watching closely for pricing, reagent rental terms, and the pace of menu expansion as the instrument moves toward commercial availability.